logo
Astronomers Just Solved the Mystery of the Universe's Missing Matter

Astronomers Just Solved the Mystery of the Universe's Missing Matter

Gizmodo5 hours ago

Decades ago, astronomers estimated that 'ordinary' matter (basically everything that isn't dark matter or dark energy) makes up 5% of the universe. There was just one problem—they had no idea where most of it was.
Astronomers from the Center for Astrophysics Harvard & Smithsonian (CfA) and the California Institute of Technology (Caltech) have tracked down the universe's 'missing' matter. Fast radio bursts (FRBs) indicate that over three-quarters of ordinary matter, officially called baryonic matter, exists in the form of hot, low-density gas between galaxies. With this data, they claim to have documented the first detailed measurements of ordinary matter's distribution throughout the universe.
'The decades-old 'missing baryon problem' was never about whether the matter existed,' CfA astronomer Liam Connor said in a CfA statement. 'It was always: Where is it? Now, thanks to FRBs, we know: three-quarters of it is floating between galaxies in the cosmic web.' Connor and his colleagues explain their discovery in a study published today in Nature Astronomy.
Technically, baryonic matter is matter made of protons and neutrons. However, astronomers often use the term to refer to all matter made of atoms, which makes up everything that isn't dark matter or dark energy. 'A small fraction of baryons are in stars and the interstellar medium within galaxies,' the researchers wrote in the study. The interstellar medium is the space between star systems.
Previous research suggested that much of the remaining baryonic matter was gas spread throughout the intergalactic medium—the space between galaxies. But because 'this diffuse ionized gas is notoriously difficult to measure,' the team added, scientists couldn't confirm how much of the gas existed or exactly where it was.
In the new study, the researchers relied on FRBs—quick, bright radio signals from faraway galaxies. FRBs slow down when they travel through intergalactic gas. By measuring this decrease in speed, the team could infer how much gas the signal had traversed. They investigated 60 FRBs ranging from a galaxy 11.74 million light years away to one approximately 9.1 billion light years away. The latter emitted the most distant FRB known to science, designated FRB 20230521B.
By studying FRBs, scientists confirmed that around 76% of all baryonic matter exists in the IGM, 15% in galaxy halos, and another small fraction in stars or cold galactic gas. Cosmological simulations had previously suggested this distribution, but the recent study provides direct evidence, shedding light on the movement of matter across the universe.
'Baryons are pulled into galaxies by gravity, but supermassive black holes and exploding stars can blow them back out—like a cosmic thermostat cooling things down if the temperature gets too high,' said Connor, who is the lead author of the study. 'Our results show this feedback must be efficient, blasting gas out of galaxies and into the IGM.'
'We're beginning to see the Universe's structure and composition in a whole new light, thanks to FRBs,' added Caltech astronomer and co-author Vikram Ravi. 'These brief flashes allow us to trace the otherwise invisible matter that fills the vast spaces between galaxies.'
With increasingly powerful telescopes expected to detect thousands of FRBs, who knows what other mysteries might soon come to light?

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Asciminib: High Responses in Second-Line Chronic-Phase CML
Asciminib: High Responses in Second-Line Chronic-Phase CML

Medscape

timean hour ago

  • Medscape

Asciminib: High Responses in Second-Line Chronic-Phase CML

Asciminib, a first-in-class BCR - ABL1 TKI, showed high molecular response rates and was well tolerated in the first prospective trial of its kind evaluating the drug as a dose-escalated second-line therapy for patients with chronic-phase chronic myeloid leukemia (CML) who had suboptimal responses to earlier therapies. METHODOLOGY: The interim analysis on the single-arm, open-label study, conducted at 85 trial sites in the US, included 101 patients with chronic-phase CML who discontinued a prior TKI due to intolerance or suboptimal responses. Patients were treated with at least one dose of asciminib 80 mg once daily. If BCR - ABL levels were above 1% at week 24, the dose was increased to 200 mg daily, and if BCR - ABL levels were above 0.1% at 48 weeks, the dose was increased from 80 to 200 mg daily, or from 200 mg daily to 200 mg twice daily, or patients could be taken off the study. - levels were above 1% at week 24, the dose was increased to 200 mg daily, and if - levels were above 0.1% at 48 weeks, the dose was increased from 80 to 200 mg daily, or from 200 mg daily to 200 mg twice daily, or patients could be taken off the study. Those with any grade 3 or 4 or persistent grade 2 toxicities that were refractory to optimal management were ineligible for dose escalations. Reasons for prior treatment discontinuation were due to a lack of efficacy in 56.4% and intolerance in 43.6% of patients. TAKEAWAY: At week 24, a major molecular response was achieved by 44.4% of patients, with 25.4% achieving a deep molecular response (MR4 or better). In all, 11.1% of patients were given dose escalations upon failing to achieve response milestones. Among 101 patients receiving at least one dose, asciminib was well tolerated by most patients. Asciminib's safety profile was that observed in previous studies, with no new or worsening safety findings observed. Grade 3 and higher adverse events (AEs) included hypertension (8.9 %), thrombocytopenia (6.9%), and neutropenia (5.9%). AEs overall led to dose adjustment or interruption in 26.7% of patients and discontinuation in four patients. IN PRACTICE: 'Asciminib, in contrast with other FDA-approved TKIs, binds to the ABL myristoyl pocket, which may reduce off-target effects compared to the other competitive TKI's,' said first author David Jacob Andorsky, MD, of the Rocky Mountain Cancer Centers, US Oncology Research, Boulder, Colorado. 'Results from ASC2ESCALATE, the first prospective trial of asciminib in second-line chronic-phase CML with dose escalation in patients not achieving response milestones, further support asciminib as a treatment option in second-line chronic-phase CML,' he said. 'The outcomes in patients with asciminib dose escalations continue to be explored, with analyses planned for future presentations,' Andorsky noted. SOURCE: The analysis was presented at the American Society of Clinical Oncology (ASCO) 2025 in Chicago. DISCLOSURES: This study was sponsored by Novartis Pharmaceuticals. Andorsky reported having relationships with AbbVie, AstraZeneca, Celgene, and Novartis.

Peter Mohler Named University Of Alabama's New President
Peter Mohler Named University Of Alabama's New President

Forbes

timean hour ago

  • Forbes

Peter Mohler Named University Of Alabama's New President

The University of Alabama has named Peter J. Mohler to be its next president, succeeding Stuart ... More Bell. The University of Alabama System Board of Trustees has unanimously selected Peter J. Mohler to become the 30th president of the University of Alabama, the state's flagship university. He will begin his appointment on July 21, succeeding Stuart Bell, who has been the university's president since 2015. Mohler currently is the executive vice president for research, innovation and knowledge at The Ohio State University and also the chief scientific officer of OSU's Wexner Medical Center. Prior to that, he served for a period as Ohio State's acting president in 2023. 'Dr. Mohler is uniquely equipped to build upon the University of Alabama's strong foundation and lead this institution into an even brighter future,' said UA System Chancellor Sid J. Trant, in a university news release. 'He is a champion for the power of public higher education to transform lives and communities through teaching, research and service, and he will advance our flagship mission through his bold, student-centered and visionary leadership,' added Trant. Mohler is credited with being an advocate for increased educational access and student success, and for supporting programs that promoted stronger graduation outcomes. Mohler earned his bachelor's degree in biology from Wake Forest University and his doctorate in cell and molecular physiology from the University of North Carolina at Chapel Hill. He received a postdoctoral fellowship in the Howard Hughes Medical Institute at Duke University before serving as a faculty member at Vanderbilt University and then later the University of Iowa. A prolific researcher, Mohler has published more than 275 peer-reviewed articles in journals such as Nature, Cell, Nature Medicine, and the New England Journal of Medicine. His research program has been focused on exploring the genetic and cellular mechanisms underlying abnormal heart rhythms and heart failure and developing new diagnostics and therapies for heart disease. Among his many awards, Mohler has been named a Pew Scholar, an Outstanding Investigator of the American Heart Association and an NIH National Heart Lung and Blood Institute Outstanding Investigator. He also has served on the editorial boards of several academic journals. At Ohio State since 2011, Mohler held a number of leadership positions. He served as the director of the Dorothy M. Davis Heart and Lung Research Institute, chair of the department of physiology and cell biology, vice dean of research in the College of Medicine, and vice president for research for the university. Mohler said it was 'a tremendous honor' to be chosen as the next president of the University of Alabama. 'I am deeply grateful to the University of Alabama System Board of Trustees for the opportunity to serve this institution and further its tradition of excellence. UA stands as a national leader in higher education, and I look forward to working collaboratively across campus, the UA System and the state to expand our impact and build on the University's remarkable momentum,' he added. Calling Mohler a 'highly respected and forward-thinking leader,' UA System Board of Trustees President Pro Tempore Scott Phelps said, 'his leadership will attract world-class faculty, staff and students and will ensure they are prepared to thrive and succeed on campus and beyond."

Study finds planetary waves linked to wild summer weather have tripled since 1950
Study finds planetary waves linked to wild summer weather have tripled since 1950

Washington Post

timean hour ago

  • Washington Post

Study finds planetary waves linked to wild summer weather have tripled since 1950

WASHINGTON — Climate change has tripled the frequency of atmospheric wave events linked to extreme summer weather in the last 75 years and that may explain why long-range computer forecasts keep underestimating the surge in killer heat waves, droughts and floods, a new study says. In the 1950s, Earth averaged about one extreme weather-inducing planetary wave event a summer, but now it is getting about three per summer, according to a study in Monday's Proceedings of the National Academy of Sciences. Planetary waves are connected to 2021's deadly and unprecedented Pacific Northwest heat wave , the 2010 Russian heatwave and Pakistan flooding and the 2003 killer European heatwave , the study said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store